Posted inNews

Covaxin for kids: Study says robust safety, immunogenicity in 2-18-year-old volunteers

Hyderabad: Bharat Biotech International Limited (BBIL) on Thursday announced that BBV152 (Covaxin), its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Bharat Biotech had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity of Covaxin in healthy children […]